CellGEN Therapies (GMP unit)

CellGEN Therapies produces advanced gene-, cell- and tissue-therapeutic products (ATMPs) for early phase clinical trials according to good manufacturing principles (GMP).

We focuss on the development and production of small batches of ATMPs or RNA vaccines as required for personalized medicines or phase I studies. In this way, we preferentially interact with academic researchers as well as companies that have developed personalized ATMPs.

We help UZ Gent, external clients and partners to move their research “from bench to bedside” by providing the right expertise, equipment and a licensed facility for the production of small batches of cell and gene therapeutics.

CellGENTherapies was founded in 2014. In 2016 the first ATMP was produced under GMP conditions. Ever since, the activity has been growing and other technologies became part of the portfolio. CellGENTherapies is currently licensed for the production of investigational advanced therapy medicinal products and will apply in 2024 for a license for the production of microbial vaccines. 

To house the expanding activities, a new GMP unit will be constructed on the site of UZ Gent (Ghent University Hospital) and should be fully operational by mid 2025.

Our location on the campus of Ghent University Hospital ensures synergies with both the hospital and Ghent University. It also benefits from Ghent’s reputation as a leading cluster for biotech and medical companies, and its position as a gateway to Europe and the world

The unit is headed by Prof. Bart Vandekerckhove. Visit the website of CellGENTherapies to discover the whole team

Products:

• Dendritic cells
• Lipid nanoparticles
• In-vitro transcribed RNA
• Stromal vascular fraction (SVF)
• Multivirus-specific T-cells
• Point-of-care CAR-T cells

Services

• Technology transfer
• Manufacturing of iATMP
• Writing of IMPDs
• Quality testing

• All info via the website https://gmp-unit.be/
• Location: UZ Gent campus (entrance 71, route 724) - Corneel Heymanslaan 10, 9000 Gent